C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma

被引:53
作者
Gerhardt, Thomas
Milz, Sabine
Schepke, Michael
Feldmann, Georg
Wolff, Martin
Sauerbruch, Tilman
Dumoulin, Franz Ludwig
机构
[1] Univ Hosp, Dept Internal Med 1, D-53105 Bonn, Germany
[2] Univ Hosp, Dept Surg, D-53105 Bonn, Germany
关键词
perihilar cholangiocarcinoma; prognostic factors; C-reactive protein; resection; outcome;
D O I
10.3748/wjg.v12.i34.5495
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate prognostic indicators for the outcome of patients with perihilar extrahepatic cholangiocarcinoma in an unselected cohort. METHODS: We retrospectively analyzed 98 patients with perihilar cholangiocarcinoma. Twenty-three patients (23.5%) underwent tumor resection. Patients with nonresectable tumors underwent either transpapillary or percutaneous transhepatic biliary drainage. Additionally, 32 patients (32.7%) received photodynamic therapy (PDT) and 18 patients (18.4%) systemic chemotherapy. Predefined variables at the time of diagnosis and characteristics considering the mode of treatment were entered into a Cox's proportional hazards model. Included in the analysis were age, tumor stage following the modified Bismuth-Corlette classification, bilirubin, prothrombin time (PT), C-reactive protein (CRP), carbohydrate antigen 19-9 (CA19-9), history of weight loss, surgical resection, chemotherapy and PDT. RESULTS: The Kaplan-Meier estimate of overall median survival was 10.5 (95% CI: 8.4-12.6) mo. In the univariate analysis, low Bismuth stage, low CRP and surgical resection correlated significantly with better survival. In the multivariate analysis, only CRP (P = 0.005) and surgical resection (P = 0.029) were found to be independently predictive of survival in the cohort. Receiver operating characteristic (ROC) analysis identified a CRP level of 11.75 mg/L as the value associated with the highest sensitivity and specificity predicting a survival > 5 mo. Applying Kaplan-Meier analysis, patients with a CRP < 12 mg/L at the time of diagnosis had a significantly longer median survival than patients with higher values (16.2 vs 7.6 mo; P = 0.009). CONCLUSION: This retrospective analysis identified CRP level at the time of diagnosis as a novel indicator for the prognosis of patients with perihilar cholangiocarcinoma. It should be evaluated in future prospective trials on this entity. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:5495 / 5500
页数:6
相关论文
共 40 条
  • [1] Photodynamic therapy for advanced bile duct cancer:: Evidence for improved palliation and extended survival
    Berr, F
    Wiedmann, M
    Tannapfel, A
    Halm, U
    Kohlhaw, KR
    Schmidt, F
    Wittekind, C
    Hauss, J
    Mössner, J
    [J]. HEPATOLOGY, 2000, 31 (02) : 291 - 298
  • [2] MANAGEMENT STRATEGIES IN RESECTION FOR HILAR CHOLANGIOCARCINOMA
    BISMUTH, H
    NAKACHE, R
    DIAMOND, T
    [J]. ANNALS OF SURGERY, 1992, 215 (01) : 31 - 38
  • [3] CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P171, DOI 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO
  • [4] 2-2
  • [5] ACUTE-PHASE RESPONSE OF HUMAN HEPATOCYTES - REGULATION OF ACUTE-PHASE PROTEIN-SYNTHESIS BY INTERLEUKIN-6
    CASTELL, JV
    GOMEZLECHON, MJ
    DAVID, M
    FABRA, R
    TRULLENQUE, R
    HEINRICH, PC
    [J]. HEPATOLOGY, 1990, 12 (05) : 1179 - 1186
  • [6] Peripheral cholangiocarcinoma (cholangiocellular carcinoma): Clinical features, diagnosis and treatment
    Chen, MF
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (12) : 1144 - 1149
  • [7] Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma
    Dumoulin, FL
    Gerhardt, T
    Fuchs, S
    Scheurlen, C
    Neubrand, M
    Layer, G
    Sauerbruch, T
    [J]. GASTROINTESTINAL ENDOSCOPY, 2003, 57 (07) : 860 - 867
  • [8] FALCONER JS, 1995, CANCER, V75, P2077, DOI 10.1002/1097-0142(19950415)75:8<2077::AID-CNCR2820750808>3.0.CO
  • [9] 2-9
  • [10] Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma - Validation of utility as a clinical marker
    Goydos, JS
    Brumfield, AM
    Frezza, E
    Booth, A
    Lotze, MT
    Carty, SE
    [J]. ANNALS OF SURGERY, 1998, 227 (03) : 398 - 404